ArticleNPJ breast cancer2026

Anlotinib-containing regimens in HR+ advanced breast cancer after prior CDK4/6 inhibitor progression.

Yifei Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.